HHS Logo U.S. Department of Health & Human Services Divider arrow NIH logo National Institutes of Health Alt desc
Skip Over Navigation Links
Strategic Alliances

Invention E-134-2010/0

Selective 12-Human Lipoxygenase Inhibitors for the Treatment of Diabetes and Clotting

Lead Inventor: David Maloney (NCATS)
Inventors: Theodore Holman (University of California, Santa Cruz), Jerry Nadler (Eastern Virginia Medical School), Michael Holinstat (Thomas Jefferson University), Anton Simeonov (NCATS), Ajit Jadhav (NCATS)
Ref. No.: E-134-2010/0

Abstract: This invention discloses small molecule inhibitors of human 12-lipoxygenase (12-hLO). 12-lipoxygenase expression, activation, and lipid metabolites have been implicated in type 1 and type 2 diabetes, cardiovascular disease, hypertension, Alzheimer's, and Parkinson's disease. The development of 12-hLO inhibitors may be a potent intracellular approach to decreasing the ability of platelets to form large clots in response to vessel injury or activation of the coagulation pathway.

Publications:

Protein Kinase C Regulation of 12-Lipoxygenase-Mediated Human Platelet ActivationMolecular Pharmacology
March 2012 • Probe Development Branch, NCATS Chemical Genomics Center

Discovery of Potent and Selective Inhibitors of Human Platelet-Type 12-LipoxygenaseJournal of Medicinal
Chemistry
• Aug. 11, 2011 • Probe Development Branch, NCATS Chemical Genomics Center

12-Lipoxygenase: A Potential Target for Novel Anti-Platelet TherapeuticsCardiovascular & Hematologic Agents in Medicinal Chemistry • July 1, 2011 • Probe Development Branch, NCATS Chemical Genomics Center

12-Lipoxygenase Products Reduce Insulin Secretion and β-Cell Viability in Human IsletsJournal of Endocrinology
and Metabolism
• February 2010 • Probe Development Branch, NCATS Chemical Genomics Center

Resistance to Type 1 Diabetes Induction in 12-Lipoxygenase Knockout MiceJournal of Clinical Investigation
May 15, 1999 • Probe Development Branch, NCATS Chemical Genomics Center

Last updated: 03-14-2017
▲ Back to top